Gastroenteropancreatic neuroendocrine tumors
Conditions
Brief summary
Progression-free survival is defined as the time from the first injection of ¹⁷⁷Lu-oxodotreotide to the occurrence of the first documented tumor progression according to RECIST 1.1 criteria during CT follow-up.
Detailed description
Progression-free survival is defined as the time from the first injection of ¹⁷⁷Lu-oxodotreotide to the occurrence of the first documented tumor progression according to RECIST 1.1 criteria during CT follow-up. Tumor assessment is performed every 3 months after treatment initiation using CT and RECIST 1.1 criteria. ⁶⁸Ga-edotreotide PET/CT images acquired immediately before the third injection of ¹⁷⁷Lu-oxodotreotide will be independently analyzed
Interventions
Sponsors
Centre De Lutte Contre Le Cancer Eugene Marquis
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival is defined as the time from the first injection of ¹⁷⁷Lu-oxodotreotide to the occurrence of the first documented tumor progression according to RECIST 1.1 criteria during CT follow-up. | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival is defined as the time from the first injection of ¹⁷⁷Lu-oxodotreotide to the occurrence of the first documented tumor progression according to RECIST 1.1 criteria during CT follow-up. Tumor assessment is performed every 3 months after treatment initiation using CT and RECIST 1.1 criteria. ⁶⁸Ga-edotreotide PET/CT images acquired immediately before the third injection of ¹⁷⁷Lu-oxodotreotide will be independently analyzed | — |
Outcome results
None listed